Predicine to Present 9 Liquid Biopsy Studies at ASCO 2024
May 22, 2024 00:11 ET
|
Predicine
HAYWARD, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc. A leading precision oncology company, announced today that it will present data from 9 ctDNA studies at ASCO 2024,...
Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update
May 13, 2024 08:15 ET
|
Benitec Biopharma Inc.
-Positive Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in April- -The Second OPMD...
More Than 90% of Metro Areas Recorded Home Price Increases in First Quarter of 2024
May 08, 2024 07:00 ET
|
National Association of Realtors®
Washington, D.C., May 08, 2024 (GLOBE NEWSWIRE) -- Key Highlights Single-family existing-home sales prices rose in 93% of measured metro areas – 205 of 221 – in the first quarter, up from...
Benitec Biopharma to Participate in the Citizens JMP Life Science Conference
May 01, 2024 08:00 ET
|
Benitec Biopharma Inc.
HAYWARD, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel...
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
April 18, 2024 07:30 ET
|
Benitec Biopharma Inc.
-First efficacy signals demonstrated for a gene therapy under development for Oculopharyngeal Muscular Dystrophy (OPMD) which affects ~15,000 patients worldwide- - BB-301 facilitated improvements...
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million
April 18, 2024 07:00 ET
|
Benitec Biopharma Inc.
HAYWARD, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel...
UPDATE: Predicine Introduces PredicineCARE™ NGS Kit for Tumor Profiling
April 11, 2024 23:07 ET
|
Predicine
Predicine’s Decentralized Lab Testing Solution Facilitates Clinical Trials, Companion Diagnostics (CDx) Development, and Patient Testing on a Global Scale.
Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024
April 09, 2024 08:00 ET
|
Benitec Biopharma Inc.
HAYWARD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel...
Predicine Announces Collaboration with Apollomics to Develop PredicineCARE™ as a Companion Diagnostic Assay in Lung Cancer
April 05, 2024 16:21 ET
|
Predicine
Collaboration Utilizing PredicineCARE™ Blood cfDNA NGS Assay Marks Progress in Employing Comprehensive Genomic Profiling for Detection of Select Alteration
Predicine Introduces PredicineCARE™ NGS Kit for Global Clinical Trials, CDx Development and Patient Testing
April 05, 2024 16:10 ET
|
Predicine
Predicine’s Decentralized Lab Testing Solution Facilitates Clinical Trials, Companion Diagnostics (CDx) Development, and Patient Testing on a Global Scale.